Productive HIV-1 infection of primary CD4+ T cells induces mitochondrial membrane permeabilization leading to a caspase-independent cell death. by Petit, F. et al.
Productive HIV-1 Infection of Primary CD4 T Cells Induces
Mitochondrial Membrane Permeabilization Leading to a
Caspase-independent Cell Death*
Received for publication, March 26, 2001, and in revised form, August 9, 2001
Published, JBC Papers in Press, October 31, 2001, DOI 10.1074/jbc.M102671200
Fre´de´ric Petit‡§, Damien Arnoult‡§, Jean-Daniel Lelie`vre‡, Laure Moutouh-de Parseval¶,
Allan J. Hance, Pascal Schneider**, Jacques Corbeil¶, Jean Claude Ameisen‡ ‡‡,
and Je´roˆme Estaquier‡ ‡‡§§
From ‡INSERM EMI-U 9922, CHU Bichat, Universite´ Paris 7, 16 rue Henri Huchard, 75018 Paris, France, INSERM
U552, IMEA-INSERM, 46 rue Henri Huchard, 75018 Paris, France, ¶Departments of Pathology and Medicine, University
of California San Diego, La Jolla, California 92161, and **Institute of Biochemistry, University of Lausanne,
CH 1066 Epalinges, Switzerland
We have explored in vitro the mechanism by which
human immunodeficiency virus, type 1 (HIV-1) induces
cell death of primary CD4 T cells in conditions of pro-
ductive infection. Although HIV-1 infection primed phy-
tohemagglutinin-activated CD4 T cells for death in-
duced by anti-CD95 antibody, T cell death was not
prevented by a CD95-Fc decoy receptor, nor by decoy
receptors of other members of the TNFR family (TNFR1/
R2, TRAILR1/R2/OPG, TRAMP) or by various blocking
antibodies, suggesting that triggering of death recep-
tors by their cognate ligands is not involved in HIV-
induced CD4 T cell death. HIV-1 induced CD4 T cell
shrinkage, cell surface exposure of phosphatidylserine,
loss of mitochondrial membrane potential (m), and
mitochondrial release of cytochrome c and apoptosis-
inducing factor. A typical apoptotic phenotype (nuclear
chromatin condensation and fragmentation) only oc-
curred in around half of the dying cells. Treatment
with benzyloxycarbonyl-Val-Ala-Asp-fluoromethylke-
tone, a broad spectrum caspase inhibitor, prevented nu-
clear chromatin condensation and fragmentation in
HIV-infected CD4 T cells and in a cell-free system (in
which nuclei were incubated with cytoplasmic extracts
from the HIV-infected CD4 T cells). Nevertheless, ben-
zyloxycarbonyl-Val-Ala-Asp-fluoromethylketone did not
prevent mitochondrial membrane potential loss and cell
death, suggesting that caspases are dispensable for HIV-
mediated cell death. Our findings suggest a major role of
the mitochondria in the process of CD4 T cell death
induced by HIV, in which targeting of Bax to the mito-
chondria may be involved.
The depletion of CD4 T cells is a major determinant of
pathogenicity in human immunodeficiency virus type 1 (HIV-
1)1 infection. The finding that the level of the viral load estab-
lished soon after infection correlates with the rate of CD4 T cell
loss and the development of AIDS (1) supports the idea that
active HIV-1 replication directly contributes to the depletion of
CD4 T cells. Accordingly, in vitro studies have shown that
HIV-1 replication induces apoptosis in proliferating primary
CD4 T cells stimulated with PHA/IL-2 and in CD4 T cell
lines (2–6). Other findings, however, support the idea that
death of uninfected T cells also contributes to AIDS pathoge-
nicity. Both spontaneous and activation-induced apoptosis oc-
cur in vitro (7–10) and in vivo (11–13) in both infected and
uninfected T cells from HIV-1-infected individuals.
Despite intensive investigations, several important ques-
tions remain about the mechanisms through which HIV infec-
tion induces CD4 T cell death. The first, as stated above, is
whether HIV induces death in infected and/or uninfected
CD4 T cells. The second concerns the nature of the signal(s)
that initiate cell death. T cells from HIV-1-infected individuals
show enhanced cell surface expression of CD95 and exhibit
increased susceptibility in vitro to CD95-mediated cell death,
induced either by an agonistic anti-CD95 antibody, by soluble
CD95 ligand (CD95L) (14–19), or by the engagement of other
members of the tumor necrosis factor receptor (TNFR) family,
including TRAILR and TNFR1 (20, 21). HIV-mediated death of
productively infected CD4 T cells in vitro has, however, been
found to be independent of CD95/CD95L interactions (4–6),
and the possible involvement of other members of the TNF
receptor family has not been explored. Several findings suggest
that viral proteins encoded by HIV-1 (gp120 envelope glycopro-
tein, Vpr) may induce death of either infected or uninfected
CD4 T cells in productively infected CD4 T cell cultures
(22–28).
Finally, another area of uncertainty concerns the identifica-
tion of the effector pathways that lead to cell death following
HIV infection. It has been reported that treatment of HIV-
* This work was supported by INSERM, Universite´ Paris 7, and
grants from Agence Nationale de la Recherche sur le SIDA (ANRS),
Sidaction, Universite´ Paris 7, Fondation de la Recherche Me´dicale (to
J. C. A.), a Human Science Frontier Program fellowship (to J. E.), a
Sidaction fellowship (to F. P.), an ANRS fellowship (to J. D. L.), and a
De´le´gation Ge´ne´rale de l’Armement fellowship (to D. A.). The part of
the work performed at the University of California, San Diego (USCD),
was supported by the UCSD Center for AIDS Research and Develop-
ment Grant NIAID 5 P30 AI 36214; National Institutes of Health
Grants AI 27670, AI 38858, AI 36214, and AI 29164; and the Research
Center for AIDS and HIV Infection of the San Diego Department of
Veterans Affairs. The costs of publication of this article were defrayed
in part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§ These authors contributed equally to this work.
‡‡ These authors supervised this work.
§§ To whom correspondence should be addressed: INSERM EMI-U
9922, Faculte´ de Me´decine Bichat, 16 rue Henri Huchard, 75018 Paris,
France. Tel./Fax: 33 1 44 85 62 88; E-mail: estaquie@bichat.inserm.fr.
1 The abbreviations used are: HIV, human immunodeficiency virus;
TNF, tumor necrosis factor; TNFR, TNF receptor; mAb, monoclonal
antibody; FITC, fluorescein isothiocyanate; IL, interleukin; MOI, mul-
tiplicity of infection; HM, heavy membrane; PS, phosphatidylserine; PI,
propidium iodide; PHA, phytohemagglutinin; IAP, inhibitor of apo-
ptosis protein; AIF, apoptosis-inducing factor; ROS, reactive oxygen
species; m, mitochondrial membrane potential; MIF, mean intensity
of fluorescence; PARP, poly(ADP-ribose) polymerase; PBMC, peripheral
blood mononuclear cell(s); zVAD-fmk, benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone; DDI, didanosine.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 2, Issue of January 11, pp. 1477–1487, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 1477
infected cells with caspase inhibitors prevents CD4 T cell death
and results in increased viral production (4, 29), whereas other
studies have found that caspase inhibitors did not prevent the
death of infected CD4 T cells (5). Two pathways are known to
be important for transducing death signals to the apoptotic
machinery. The “extrinsic” pathway involves activation of
death receptors and recruit procaspase-8 through FADD (30,
31). Downstream of caspase-8, two pathways have been re-
ported; caspase-8 may either directly activate caspase-3 or
cleave Bid (a proapoptotic member of the Bcl-2 family), induc-
ing the release of cytochrome c from mitochondria. Cytochrome
c, together with Apaf-1, activates caspase-9, leading to the
activation of the caspase-3 (32–34). The “intrinsic” pathway is
death receptor-independent; stress signals activate proapo-
ptotic members of the Bcl-2 family (Bax, Bak, etc.) and induce
the permeabilization of the mitochondria and the release of
apoptogenic factors (35). Although caspases are essential effec-
tors of the nuclear apoptotic phenotype (chromatin condensa-
tion and fragmentation), evidence from experimental systems
using broad spectrum caspase inhibitors support the notion
that programmed cell death can proceed in a caspase-independ-
ent manner (36–39). Moreover, recent reports have suggested
that caspase inhibitors, which inhibit apoptosis induced by
diverse stimuli, lead to the appearance of dead cells expressing
necrotic-like phenotype (40–42). Cellular mechanisms that ac-
count for caspase-independent programmed cell death are still
elusive and may involve release by mitochondria of effectors
such as apoptosis-inducing factor (AIF) (43).
To further characterize the mechanisms responsible for cell
death induced by HIV-1, freshly isolated CD4 T cells were
infected with HIV-1 and stimulated with PHA/IL-2. We ob-
served that only around half of the dying CD4 T cells dis-
played a typical apoptotic phenotype (cell shrinkage, chromatin
condensation, and fragmentation), the other half showing a
nonapoptotic cell death phenotype (membrane permeabiliza-
tion and intact nucleus) that only shared one feature with
apoptosis (cell shrinkage). Treatment with zVAD-fmk, a broad
caspase inhibitor, prevented the induction of an apoptotic phe-
notype (nuclear chromatin condensation and fragmentation) in
the HIV-infected CD4 T cells but did not prevent loss in
mitochondrial membrane potential (m) and cell death. Our
results support a scenario in which disruption of the mitochon-
dria membrane permeability is a central event in cell death
following HIV-1 infection.
MATERIALS AND METHODS
Reagents, Antibodies, and Cytokines—Murine monoclonal antibod-
ies with the following specificities were used: CD14, CD19, CD56, and
CD8 (Pharmingen, San Diego, CA); agonistic anti-CD95 mAb (CH11
and 7C11) (Coulter Corp., Miami, FL); antagonistic anti-CD95 mAb
(ZB4) (Coulter Corp.); antagonistic anti-TNFR1 and -TNFR2 mAbs
(R&D Systems); neutralizing anti-TNF antibody (R&D Systems). Sol-
uble decoy proteins were human CD95-Fc immunoglobulin fusion
protein (binds CD95L) purchased from Alexis Corp. (San Diego, CA),
TRAILR1-Fc, TRAILR2-Fc (binds TRAIL), OPG-Fc (binds RANKL
and TRAIL), TNFR1-Fc (binds TNF and lymphotoxin ), and TRAMP/
DR3-Fc (orphan receptor) produced as described (44, 45). Labeled
antibodies were as follows: PercP-labeled CD4 mAb (Leu 3a; Becton
Dickinson, Mountain View, CA); PC5-labeled CD4 mAb (13B8.2;
Coulter Corp.); phosphatidylethanolamine-labeled anti-p24 antigen
(KC-57; Coulter Corp.); FITC-labeled anti-Bcl-2 (124; DAKO,
Trappes, France). For Western blotting we used a rabbit polyclonal
anti-caspase-3 (Pharmingen, San Diego, CA), a rabbit polyclonal anti-
caspase-9 (Cayman Chemicals, Ann Arbor, MI), a mouse IgG2b anti-
caspase-8 (5F7; Upstate Biotechnology, Inc., Lake Placid, NY), a
mouse IgG1 anti-PARP (C2-10; Pharmingen), a mouse IgG1 anti-
survivin (MAB747; R&D Systems), a mouse IgG1 anti-c-IAP1 (B75-1;
Pharmingen), and a mouse anti-actin (AC40; Sigma). Cytochrome c
was probed with a mouse IgG2b anti-cytochrome c (7H8.2C12;
Pharmingen), and AIF was probed with a rabbit polyclonal anti-AIF
obtained from rabbit immunized against a mixture of three different
human AIF peptides (amino acids 106–120, 512–526, and 588–602).
Bax and VDAC were probed with a mouse IgG1 anti-Bax (6A7;
Pharmingen) and a mouse anti-VDAC (Calbiochem). Recombinant
human IL-2 was kindly provided by Chiron Corp. (Emeryville, CA).
Other reagents were annexin-V-FITC (Coulter Corp.), propidium io-
dide and DiOC6 (Molecular Probes, Inc., Eugene, OR), and Hoechst
33342 (Sigma). Caspase inhibitor zVAD-fmk was purchased from
Calbiochem, while DDI, a reverse transcriptase inhibitor, was pur-
chased from Sigma.
Cells and Culture Conditions—Heparinized venous peripheral blood
was obtained from HIV-seronegative healthy donors. PBMC were iso-
lated by Ficoll-Hypaque density gradient centrifugation and cultured in
RPMI 1640 (Invitrogen) supplemented with 10% heat-inactivated fetal
bovine serum (Summit Biotechnology, Greeley, CO), 2 mM L-glutamine,
1 mM sodium pyruvate (Invitrogen), and penicillin/streptomycin (In-
vitrogen). When indicated, purified CD4 T cells were obtained by
depleting PBMC of B cells, NK cells, and CD8 T cells by negative
selection, using CD19, CD56, and CD8 mAbs and magnetic beads
coated with anti-mouse IgG (Dynal, Lake Success, NY). PBMC were
incubated in the absence or presence of virus at the indicated multi-
plicity of infection (MOI) for 2 h at 37 °C. After two washes, the cells
were resuspended in complete medium in the absence or presence of 1
g/ml PHA-P (Sigma) and 100 IU/ml IL-2. When indicated, CD4 T
cells were incubated with either agonistic CD95 mAb or Fc decoy
receptors. HIV p24 antigen was measured by an enzyme immunoassay
as described by the manufacturer (Abbott). Intracellular p24 antigen
was also assessed by flow cytometry after fixation and permeabilization
of CD4 T cells with Intraprep permeabilization reagent (Coulter
Corp.).
Test of Decoy Receptors—Efficiency of decoy receptors was tested as
described. Jurkat cells were incubated with FLAG-TRAIL (400 ng/ml)
and cross-linked with anti-FLAG M2 (2 g/ml) in the absence or pres-
ence of decoy receptors (TRAILR1-Fc, TRAILR2-Fc, OPG-Fc) (40 g/ml)
for 16 h, and apoptosis was monitored by flow cytometry using annexin-
V-FITC. WEHI 164 cells were incubated with TNF in the absence or
presence of TNFR1-Fc (40 g/ml) for 16 h. Living cells were stained
with the PMS/MTS test (phenazine methosulfate/3-[4,5-dimethylthia-
zol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium,
inner salt) as previously described (44).
Virus Preparation—High titer stocks of the laboratory strain HIV-
1LAI (10
6 TCID50/ml) were prepared by inoculating CEM at an MOI of
0.001 and growing the cells for 10 days. 10 ml of this culture were added
to 400 ml of uninfected CEM (5  105 cells/ml) and grown for 5–7 days
until abundant syncytia were present. The cells were pelleted (300  g
for 10 min) and resuspended in one-one hundredth of the initial volume
for 8 h. The supernatant was clarified by centrifugation (800  g for 10
min).
Measurement of Cell Death—Nuclear condensation and fragmenta-
tion (typical morphological changes of apoptosis) was visualized by UV
microscopy using Hoechst 33342 nuclear dye. Cells were also double-
stained with propidium iodide and Hoechst 33342 to distinguish apo-
ptotic cells from cells that lost membrane integrity. Intact blue nuclei,
condensed fragmented blue-pink nuclei, and intact pink nuclei were
considered viable, apoptotic (early and late), and nonapoptotic cells,
respectively. Cells were also analyzed by light microscopy using trypan
blue dye reagent (Sigma). Live cells showed normal refringent cyto-
plasm, apoptotic cells displayed typical chromatin condensation and
fragmentation and excluded trypan blue, and nonapoptotic cells were
trypan blue positive, as previously described (7, 15, 18, 46). By flow
cytometry, we determined dying cells using FITC-conjugated an-
nexin-V, and to evaluate m, cells were stained with DiOC6. Nuclear
condensation and fragmentation was also assessed by flow cytometry
using propidium iodide.
Western Blotting—For total extracts, cells were incubated in SDS
lysis buffer, boiled for 10 min, and centrifuged for 15 min at room
temperature. Total protein was measured using the DC protein assay
(Bio-Rad). Equal amounts of proteins were boiled for 5 min in 2
Laemmli sample buffer with -mercaptoethanol and run on a 4/20%
polyacrylamide gel (Bio-Rad). Proteins were transferred to a polyvinyli-
dene difluoride membrane (Bio-Rad) and immunoblotted with specific
antibodies. Western blots were then visualized using horseradish per-
oxidase-conjugated secondary antibodies (Amersham Biosciences, Inc.),
followed by enhanced chemiluminescence (Amersham Biosciences).
For detection of cytochrome c and AIF, cells were incubated in cell
extract buffer (50 mM PIPES, pH 7.4, 50 mM KCl, 5 mM EGTA, 2 mM
MgCl2, 1 mM dithiothreitol, 10 M cytochalasin B, and 1 mM phenyl-
methylsulfonyl fluoride) for 30 min at 4 °C, homogenized with a Dounce
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homogenizer, and centrifuged at 14,000  g for 30 min at 4 °C. The
supernatant was removed and stored as cytosolic fraction.
The mitochondria-enriched heavy membrane (HM) fraction was pre-
pared as follows. Cells were washed in isotonic buffer (10 mM HEPES,
pH 7.5, 200 mM mannitol, 70 mM sucrose, 1 mM EGTA) supplemented
with a mixture of protease inhibitors (Roche Molecular Biochemicals)
and homogenized with a Dounce homogenizer. Nuclei and unbroken
cells were separated at 120  g for 5 min. The supernatant was centri-
fuged at 10,000  g for 30 min to collect HM pellet.
Cell-free Extracts—Cytoplasmic extracts were derived from unin-
fected and HIV-infected primary CD4 T cells stimulated with PHA/
IL-2. Cytoplasmic extracts from Jurkat T cells incubated in the absence
or presence of CD95 mAbs (7C11, Coulter Corp.) for 4 h were also used
as a control. Cell-free extracts and nuclei from CEM cells were prepared
as previously described (47). Briefly, cytoplasmic extracts were pre-
pared as follows. Cells were washed twice in phosphate-buffered saline
and incubated on ice for 20 min with cell extract buffer. Cells were lysed
with a B-type pestle. Lysis was monitored by phase-contrast micros-
copy. The cell lysate was centrifuged at 4 °C for 15 min at 17,000  g,
and the clear cytosol was carefully removed. CEM nuclei were prepared
as follows. CEM cells were washed twice in phosphate-buffered saline
and once in nuclei isolation buffer (10 mM PIPES, pH 7.4, 10 mM KCl,
2 mM MgCl2, 1 mM dithiothreitol, 10 M cytochalasin B, and 1 mM
phenylmethylsulfonyl fluoride), resuspended in nuclei isolation buffer,
allowed to swell on ice for 20 min, and gently lysed with a Dounce
homogenizer. Liberated nuclei were then layered over 30% sucrose in
nuclei isolation buffer and centrifuged at 800  g for 10 min, followed
by washing in nuclei isolation buffer and resuspension in nuclei storage
buffer (10 mM PIPES, pH 7.4, 80 mM KCl, 20 mM NaCl, 250 mM sucrose,
5 mM EGTA, 1 mM dithiothreitol, 0.5 mM spermidine, 0.2 mM spermine,
1 mM phenylmethylsulfonyl fluoride, and 50% glycerol) at 2  108
nuclei/ml. Nuclei were stored at 80 °C until use.
Cell-free reactions (25 l) comprised 20 l of cytoplasmic extract
(2–10 mg/ml protein), 1 l (2 105) of nuclei, and 4 l of extract dilution
buffer (10 mM HEPES, 50 mM NaCl, 2 mM MgCl2, 5 mM EGTA, 1 mM
dithiothreitol, 2 mM ATP, 10 mM phosphocreatine, and 50 g/ml crea-
tine kinase).
Cell Surface Staining—Two-color flow cytofluorometric analysis
(FACScan; Becton Dickinson) was performed by co-staining cells with
mAbs (including isotype controls) directly labeled with phosphati-
dylethanolamine or PercP. Lymphocytes were gated by forward and
side scatter parameters.
Statistical Analysis—Statistical significance (p) was assessed using
the paired Student’s t test as indicated in the figure legends.
RESULTS
Productive HIV Infection of Primary CD4 T Cells Induces
both Typical Apoptosis and Nonapoptotic Cell Death—Resting
PBMC from healthy donors were incubated for 2 h with the
laboratory strain HIV-1LAI. After removing unbound residual
virus, T cells were stimulated with PHA and IL-2 for 4 days,
and cell death and viral production were assessed. Both cell
death and viral replication (assessed by p24 expression) in-
creased with the inoculum (Fig. 1A). Absolute numbers of
CD4 T cells were decreased in the infected cultures, the
extent of depletion being proportional to the viral input (Fig.
1B). Cytofluorimetric analysis of T cell populations indicated
that after 4 days of PHA and IL-2 stimulation, 10% of CD4
T cells from six different donors inoculated with HIV-1LAI re-
mained in the culture, compared with 55% in the uninfected
cultures (Fig. 1C). Cell death preceded any significant appear-
ance of syncytia in the culture (data not shown).
In order to exclude the possibility that HIV-induced CD4 T
cell death in the cultures resulted (at least in part) from CD8
T cell-mediated killing, we purified CD4 T cells by negative
selection prior incubation with HIV-1LAI and PHA/IL-2 stimu-
lation (Fig. 1D). In these conditions (as in unfractionated
PBMC), HIV-1LAI induced CD4 T cell depletion. This strongly
suggested that viral-induced CD4 T cell depletion occurred
independently of participation of additional lymphoid cells,
such as CD8 T cells, NK cells, or B cells.
Approximately 50% of the HIV-infected cells displayed cell
shrinkage (Fig. 2, B and E), phosphatidylserine (PS) exposure
(Fig. 2, C and E) and loss in m (Fig. 2, D and E). In contrast,
nuclear chromatin condensation and fragmentation typical of
apoptosis, as visualized by UV microscopy using Hoechst 33342
nuclear dye (Fig. 2A), was observed in only 20–30% of CD4 T
cells in the HIV-infected cultures (Fig. 2E). Thus, half of the
dying CD4 T cells displayed typical apoptosis, and the other
half displayed a nonapoptotic cell death phenotype character-
ized by lack of nuclear chromatin condensation and fragmen-
tation associated with a loss in membrane integrity (Fig. 2E).
By double staining using annexin-V, which detects PS expo-
sure, and propidium iodide (PI), which measures membrane
integrity, HIV-infected cultures contained both annexin-V-pos-
itive/PI-negative CD4 T cells (apoptotic) and annexin-V-pos-
itive/PI-positive CD4 T cells (nonapoptotic) (20.5  6 and
32.3  8%, respectively; data not shown). Altogether, these
data suggest that HIV induces both typical apoptosis and an
additional phenotype of cell death. The latter was distinct from
necrosis (membrane permeability and cell swelling), since
CD4 T cells displayed a membrane permeability associated
with a cell shrinkage.
Antagonists of the TNFR Family Members Do Not Prevent
HIV-1LAI-mediated CD4 T Cell Death—As shown in Fig. 3, A
and B, when CD4 T cells were incubated with HIV-1LAI and
stimulated by PHA/IL-2, CD4 T cells were primed for cell
FIG. 1. CD4 T cell depletion induced by productive infection of
PBMC with HIV-1LAI following PHA/IL-2 stimulation. PBMC from
normal donors were incubated for 2 h with either medium alone (None)
or with HIV-1LAI at various MOI (0.0001–0.1), washed, and cultured for
4 days in the presence of PHA and IL-2. After the 4-day culture, the
following parameters were assessed. A, absolute numbers of surviving
cells (f); viral replication () as assessed by p24 antigen in the cell
supernatants. B, absolute numbers of surviving CD4 T cells calcu-
lated by the counting of absolute numbers of surviving cells in a hemo-
cytometer and analyzing the percentage of CD4 T cells by flow cytom-
etry. The experiment presented is representative of three experiments
performed. C, percentages of CD4 and CD8 T cells, assessed using
flow cytometry in PBMC from six different donors (each symbol repre-
sents results from one individual) cultured for 4 days in the presence of
PHA/IL-2 after incubation with medium alone (HIV) or with HIV-1LAI
(HIV) at a MOI of 0.1. Bars represent mean values in each group.
Statistical significance was assessed using the paired Student’s t test.
D, CD4 T cells were purified from PBMC of normal donors using
negative selection and then incubated for 2 h with either medium
(None) or HIV-1LAI (HIV) at a MOI of 0.01, washed, and cultured for
6 days with PHA/IL-2. Viable cells were counted by microscopic analy-
sis. Results are the mean of five independent experiments.
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death in response to antibody-mediated CD95 ligation at day 4.
In contrast, uninfected activated CD4 T cells became sensi-
tive to CD95 ligation-mediated death at day 6, as previously
described (48) (data not shown). Although HIV-infected CD4
T cells became sensitive to CD95 ligation, this process ap-
peared not to account for their subsequent death in the absence
of any CD95 antibody treatment. Indeed, when cultures were
treated 3 days after PHA/IL-2 stimulation with a neutralizing
mAb (ZB4) or a CD95-Fc decoy receptor (which prevents inter-
action between CD95L and CD95 (49)), CD4 T cell death ob-
served 3 days later was not prevented (Fig. 3C). Similarly, no
preventive effect was observed when CD95-Fc was added at
day 1 following PHA stimulation (data not shown). The cellular
localization of CD95L was examined (50) by isolating cytosolic
FIG. 2. CD4 T cell depletion involved both apoptotic and non-
apoptotic cell death. CD4 T cells were purified, incubated for 2 h
with either medium (uninfected) or HIV-1LAI (HIV-infected) at a MOI of
0.01, washed, and cultured with PHA/IL-2 for 6 days. A, chromatin
condensation and fragmentation was visualized by UV fluorescence
microscopy using Hoechst 33342. B, shrunken cells were visualized by
flow cytometry with relatively high side scatter and low forward scatter
properties. C, PS exposure was determined using annexin-V-FITC. D,
m was assessed using mitochondrial dye reagent DiOC6. E, mean of
four independent experiments. Apoptotic and nonapoptotic cells were
visualized by light microscopy using trypan blue dye reagent. Apoptotic
cells (Apo) displayed translucent cytoplasm and condensed nuclei but
excluded trypan blue dye reagent, nonapoptotic cells (Non Apo) were
blue cells, and live cells displayed refringent cytoplasm. 300 cells were
counted in duplicate.
FIG. 3. CD4 T cell depletion induced by HIV-1 infection follow-
ing PHA/IL-2 stimulation does not involve members of the TNF
receptor family. To assess sensitivity of CD4 T cells to CD95 liga-
tion-mediated cell death, CD4 T cells were purified, incubated for 2 h
with either medium () or HIV-1LAI (f) at a MOI of 0.005, washed, and
cultured for 4 days with PHA/IL-2. Cells, isolated through Ficoll-
Hypaque density gradient centrifugation, were then incubated for 6 h in
the absence () or presence () of 1 g/ml of an agonistic anti-CD95
antibody (CD95 mAbs). A, the absolute numbers of surviving CD4 T
cells remaining in the culture; B, the percentages of dying CD4 T cells
in the same cultures, as indicated by flow cytometric analysis using
CD4 antibody and annexin-V double labeling. Results are the mean of
three experiments performed. C, to assess the role of the death recep-
tors, CD4 T cells were purified, incubated for 2 h with HIV-1LAI at a
MOI of 0.01, washed, and cultured for 3 days with PHA/IL-2. Cells were
then cultured for 72 h in the absence (none) or presence of neutralizing
mAbs (20 g/ml) or decoy receptors (40 g/ml) that block receptor/
ligand interactions. Shown are the percentages of dying CD4 T cells as
assessed by evaluation of annexin-V staining. Results are the mean of
three independent experiments performed. D, Jurkat and WEHI 164
cells were used as control of efficiency for decoy receptors as described
under “Materials and Methods.”
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and membrane fractions of CD4 T cells after stimulation with
PHA/IL-2 and evaluating the presence of CD95L by Western
blotting. At both days 4 and 6, CD95L (35-kDa protein) was
localized in the cytosolic fraction, not in the membrane fraction,
of both uninfected and HIV-infected CD4 T cells (data not
shown).
CD95L/CD95 is a death ligand/receptor pair of the TNF/TNF
receptor superfamily, which also includes other pairs, such as
TRAIL/TRAILR1, TRAIL/TRAILR2, and the orphan death re-
ceptor TRAMP(DR3) (51). Using either neutralizing antibodies
or decoy receptors that have been previously demonstrated to
block the interaction between ligands and receptors (44, 45, 52)
(Fig. 3D), we assessed whether HIV-mediated cell death of
CD4 T cells stimulated with PHA/IL-2 involved one or more
of these death receptors. In vitro treatment with the decoy
receptors or neutralizing antibodies 3 days after PHA/IL-2
stimulation did not prevent CD4 T cell death observed 3 days
later (Fig. 3C). These data suggest that HIV-1 triggers a cell
death pathway that is independent of the TNF receptor family
(CD95, TNFR1/TNFR2, TRAILR1/R2/OPG, TRAMP).
HIV-1LAI -mediated Cell Death Is Associated with Caspase
Activation—Caspases, the main effectors of apoptosis, are syn-
thesized as inactive procaspases that require processing to
become active (53). The current model suggests that after apo-
ptotic stimuli, activation of initiator caspases such as caspase-8
and caspase-9 leads to the proteolytic cleavage of effector
caspases such as caspase-3. To assess the role of caspases in
HIV-mediated cell death, caspases from CD4 T cells were
analyzed by Western blotting. We observed that in uninfected
and HIV-infected PHA-stimulated CD4 T cells, the amount of
proenzymes detected was increased compared with that of un-
stimulated T cells at both 4 and 6 days. Caspase-3 (32-kDa
proenzyme) was reproductively found to be processed into frag-
ments of 20 kDa after PHA/IL-2 stimulation (Fig. 4). None of
these fragments (17, 19, and 21 kDa) was observed in unstimu-
lated CD4 T cells. The observation of caspase cleavage in
PHA-activated CD4 T cells is in agreement with a recent
report showing that CD4 T cells, in contrast to transformed T
cell lines, rapidly process caspases, including caspase-3, and
caspase substrates following T cell activation (54). Although a
similar pattern was observed comparing uninfected and HIV-
infected CD4 T cells, the amount of caspase-3 proenzyme in
HIV-infected CD4 T cells at days 4 and 6 after PHA/IL-2
stimulation was decreased compared with that in uninfected
CD4 T cells (Fig. 4), suggesting an increased processing of the
proenzyme in the HIV-infected CD4 T cells. Activation of the
initiator caspases was also assessed using antibodies against
caspase-8 and -9. Western blotting showed that after stimula-
tion with PHA/IL-2 caspase-8 was processed into 43–45-kDa
fragments, but the 18-kDa active subunit was detected at day
6 only in HIV-infected CD4 T cells. In addition, the amount
of proenzymes in HIV-infected CD4 T cells drastically de-
creased at day 6 compared with that in uninfected CD4 T
cells (Fig. 4). In the same extracts, caspase-9 (46 kDa) was
processed into a 37-kDa fragment following PHA/IL-2 stimula-
tion in both uninfected and HIV-infected CD4 T cultures. The
amount of proenzyme decreased at days 4 and 6 in HIV-in-
fected CD4 T cells, compared with that of uninfected CD4 T
cells (Fig. 4). Altogether, these results suggest that HIV-1
infection induces procaspases processing. Since caspase-3 was
activated after PHA/IL-2 stimulation, we determined whether
caspase substrates were also processed in stimulated CD4 T
cells. PARP (115 kDa) is one of the caspase-3 substrates
cleaved during apoptosis (55). Stimulation with PHA/IL-2 in-
creased PARP protein levels, confirming previous reports
showing an up-regulation of PARP and its cleavage in stimu-
lated primary T cells (54). Concomitant with its induction, 80%
of PARP was found processed into an 85-kDa fragment in
PHA-stimulated CD4 T cells, whether or not they were in-
fected with HIV-1 (Fig. 4).
Inhibitor of Apoptosis Proteins (IAPs) have been proposed to
inhibit caspases in more distal portions of the cell death path-
way, downstream of cytochrome c (56, 57). Western blotting of
c-IAP1 and survivin (Fig. 5) revealed that the amount of c-IAP1
was much lower in the cytosolic fraction of HIV-infected CD4
T cells compared with that in uninfected CD4 T cells (c-IAP1
protein was decreased by 60% in two independent experi-
ments). In contrast, no major difference in the expression of
survivin protein was observed when comparing HIV-infected
and uninfected CD4 T cells (a difference of less than 10% was
observed). These data indicate that cell death of productively
HIV-infected CD4 T cells is associated with a decrease in
c-IAP1 expression.
We next determined the apoptogenic effect of cytoplasmic
extracts on isolated CEM nuclei in a cell-free system. In these
studies, cytosolic fractions of PHA-stimulated CD4 T cells
from uninfected and HIV-infected cultures were compared. The
proportion of dying cells, as assessed by evaluation of PS expo-
sure, was 20.2 and 66.5% in uninfected and HIV-infected cul-
tures, respectively (data not shown). As a control, we used
cytoplasmic extracts prepared from Jurkat T cells treated or
not with CD95 mAbs. The cytosolic fraction of HIV-infected
FIG. 4. Procaspase processing in uninfected and HIV-infected
CD4 T cells following PHA/IL-2 stimulation. CD4 T cells were
purified from PBMC of normal donors using negative selection and then
incubated for 2 h with either medium () or HIV-1LAI () at a MOI of
0.01, washed, and cultured for 4 (4d) or 6 days (6d) with PHA/IL-2 ()
or without stimulation (). Extracts from uninfected and HIV-infected
CD4 T cells were analyzed for caspase-3, caspase-8, caspase-9, and
PARP by Western blotting. Extracts from Jurkat cells cultured in the
absence () or presence of CD95 mAbs () are shown as controls. For
caspase-8, the Western blot was exposed for 3 min (proenzyme) and 25
min (cleaved products). As a control of loading, actin was used. Proen-
zymes and cleaved subunits are indicated on the left by arrows. The
percentages of dying cells (% of PS cells) determined by flow cytometry
using annexin-V-FITC are indicated. The experiment is representative
of three independent experiments performed.
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CD4 T cells mediated nuclear chromatin condensation and
fragmentation as visualized by flow cytometric and microscopic
analysis (Fig. 6), as was observed in nuclei incubated with the
cytosolic fraction of CD95 mAb-treated Jurkat cells. In con-
trast, the activity of cytosol from uninfected CD4 T cells was
quite similar to the activity of cytosol from Jurkat T cells
cultured in the absence of CD95 mAbs. Next, using zVAD-fmk,
a broad caspase inhibitor, we explored whether the inhibition
of caspases prevents nuclear chromatin fragmentation and con-
densation. When cytoplasmic extracts from Jurkat T cells
treated with CD95 mAbs and HIV-infected CD4 T cells were
incubated with zVAD-fmk (50 M), the degradation of CEM
nuclei was inhibited (Fig. 6). Our data suggest that caspases
are the main effectors involved in chromatin condensation and
fragmentation during HIV-mediated cell death.
HIV-1LAI Mediated a Caspase-independent Cell Death—
Since caspase inhibitor prevented chromatin condensation and
fragmentation in a cell-free system, HIV-infected CD4 T cells
were cultured in the presence of zVAD-fmk to assess the role of
caspases in HIV-mediated cell death. The apoptotic phenotype
(chromatin condensation and fragmentation) was markedly de-
creased in cells maintained in the presence of zVAD-fmk (Fig.
7A). zVAD-fmk did not prevent m loss (Fig. 7B), PS exposure
(Fig. 7C), nor cell shrinkage (Fig. 7D). In fact, zVAD-fmk treat-
ment turned the apoptotic cell death phenotype into a nonapop-
totic cell death phenotype, as visualized by UV microscopic
analysis using Hoechst 33342/PI double staining (Fig. 7E) and
by light microscopic analysis using trypan blue dye reagent
(Fig. 7F). Thus, our data suggest that HIV induces a caspase-
independent cell death pathway that is associated with a dis-
ruption of mitochondrial membrane potential.
Involvement of Mitochondria during HIV-1LAI -mediated Cell
Death—A variety of key events during programmed cell death
focus on mitochondria, including loss of m and the release of
apoptogenic factors into the cytosol (35). To evaluate the role of
apoptogenic factors released by mitochondria in HIV-mediated
cell death, cytosolic fractions prepared from uninfected and
HIV-infected CD4 T cells were analyzed using specific anti-
bodies for the presence of cytochrome c, a 15-kDa protein that
is involved in caspase activation, and AIF, a 57-kDa protein
that is involved in caspase-independent cell death (43). Fig. 8
shows that the cytosolic fraction of HIV-infected CD4 T cells
at day 6 after PHA/IL-2 stimulation contains more cytochrome
c and more AIF than uninfected CD4 T cells, suggesting that
mitochondria from HIV-infected CD4 T cells release these
two factors.
Members of the Bcl-2 family have been shown to be involved
in the regulation of mitochondria permeability during apo-
ptosis (35). Bcl-2 expression (an antiapoptotic protein) was
assessed by flow cytometry after gating on live and dying cells.
The mean intensity of fluorescence (MIF) of Bcl-2 expression in
live cells (high forward scatter parameter) from uninfected
(MIF  46.3) and HIV-infected CD4 T cells (MIF  42.9) was
similar (Fig. 9A) and was markedly decreased in dying cells
(shrunken cells) of both uninfected and HIV-infected CD4 T
cells (MIF 30.8 and 23.2, respectively), suggesting that loss of
Bcl-2 is associated with cell death. By two-color flow cytometric
analysis, we assessed Bcl-2 expression in live productively in-
fected CD4 T cells as determined by p24 antigen expression
(Fig. 9B). Our data indicate that Bcl-2 expression was equiva-
lent in CD4 T cells in which HIV was or was not actively
replicating, suggesting that HIV-mediated cell death is not
associated with an early change in Bcl-2 expression. However,
after cell fractionation, we observed that more Bax (a proapo-
ptotic protein) was present in the mitochondria enriched HM
fraction of infected CD4 T cells (Bax protein was increased by
55% in two independent experiments) than that present in
uninfected CD4 T cells (Fig. 9D). In vitro treatment of in-
fected CD4 T cells with the reverse transcriptase inhibitor
FIG. 5. HIV-1-mediated cell death is associated with the down-
regulation of c-IAP1 protein expression. Cytosolic extracts from
uninfected () and HIV-infected CD4 T cells () at day 6 were ana-
lyzed by Western blotting for c-IAP1 and survivin expression. As a
control of loading, actin was used. The percentages of dying cells (% of
PS cells), determined by flow cytometry using annexin-V-FITC, are
indicated. The experiment is representative of two independent exper-
iments performed.
FIG. 6. HIV-1 promotes apoptotic activity in cell-free extracts.
CEM nuclei were incubated for 2 h with cytolosic extracts (CE) from
uninfected CD4 T cells (CE from Uninfected cells) or from HIV-1-
infected CD4 T cells in absence (CE from HIV-infected cells) or pres-
ence of zVAD-fmk (50 M; preincubated for 30 min) (CE from HIV-
infected cells zVAD). As a control, CEM nuclei were also incubated for
2 h with cytolosic extracts from Jurkat T cells (CE from Jurkat cells) or
from Jurkat cells treated with CD95 mAbs (100 ng/ml for 4 h at 37 °C)
in the absence (CE from CD95 mAbs treated Jurkat cells) or presence of
zVAD-fmk (50 M; preincubated 30 min) (CE from CD95 mAbs treated
Jurkat cells  zVAD). The DNA content of the nuclei was then assessed
by flow cytometry after propidium iodide staining. The insets show the
most frequent morphology of the nuclei. Nuclear morphology was ob-
served under UV fluorescence after Hoechst 33342 staining (magnifi-
cation 1000).
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DDI, which prevented cell death (PS exposure and loss in m)
(Fig. 9C), also prevented targeting of Bax to the mitochondria
(Fig. 9D). These data suggest that HIV-1 may induce CD4 T cell
death via the targeting of Bax to the mitochondria.
DISCUSSION
Our results suggest that HIV-1 induces CD4 T cell death
through a TNF receptor family-independent pathway. These
findings confirm and extend previous findings indicating that
productive infection of PHA/IL-2 stimulated primary CD4 T
cells, as well as productive infection of transformed CD4 T
cell lines, induces a process of CD4 T cell death that does not
involve CD95/CD95L interactions (4–6). Other death path-
ways, such as TRAIL/DR4 or TNF/TNFR, have been suggested
to play a role in apoptosis of T cells from HIV-infected persons
(20, 21), but decoy receptors corresponding to these and other
TNF receptor family members did not prevent HIV-mediated
death of primary CD4 T cells stimulated with PHA/IL-2,
indicating that death occurred independently of these death
receptors (CD95, TNFR1/R2/OPG, and TRAMP). In agreement
with an absence of involvement of death receptors in HIV-
mediated cell death, we did not observe an early full processing
of caspase-8. Caspase-8 is generally considered to be an initi-
ator caspase, which associates with the adaptator molecule
FADD recruited to the death receptor. Full processing of
caspase-8 in the 18-kDa active form was only observed at day 6,
suggesting that caspase-8 activation may be a late event in the
pathway leading to cell death in response to HIV infection (34).
Although HIV induced the cleavage of caspase-3, -8, and -9
proenzymes and markedly decreased the expression of c-IAP1,
an inhibitor of caspase-3, our experiments indicate that
caspases are dispensable for HIV-mediated programmed cell
death. Nevertheless, these proteases do play a role in the
nuclear apoptotic phenotype as evidenced by the effects of
zVAD-fmk. Several recent reports have suggested that caspase
inhibitors inhibit apoptosis induced by diverse stimuli but do
not prevent further cell death (36–38, 40–42, 58, 59) and lead
to the appearance of cells with a necrotic-like phenotype. Our
data show that the nonapoptotic phenotype is characterized by
membrane permeabilization and intact nuclei and shares with
the apoptotic phenotype the presence of cell shrinkage. This
experiments is representative of two independent experiments per-
formed. F, apoptotic and nonapoptotic cells were also determined by
microscopic analysis using trypan blue dye exclusion as described in the
legend to Fig. 2E. 200 cells were counted in duplicate. The data shown
are the mean of three independent experiments performed.
FIG. 7. Caspase inhibitors prevent apoptosis but not HIV-in-
duced cell death. CD4 T cells were purified, incubated for 2 h in the
absence (Uninfected) or presence of HIV-1LAI (HIV-infected) at a MOI of
0.01, washed, and cultured for 6 days with PHA/IL-2. At day 3, CD4
T cells were treated in the absence (Medium) or presence (zVAD) of the
broad caspase inhibitor zVAD-fmk (50 M). Histograms represent the
mean in chromatin condensation and fragmentation (A), loss in m
(B), PS exposure (C), or cell shrinkage (D) in three independent exper-
iments performed. E, Hoechst 33342/PI double staining shows that blue
intact nuclei were viable cells, whereas those with blue-pink condensed
and fragmented nuclei were apoptotic cells (Apo). Cells with pink intact
nuclei were considered as nonapoptotic cells (Non Apo). The percent-
ages of apoptotic and nonapoptotic CD4 T cells are indicated. The
FIG. 8. HIV-1-mediated cell death is associated with the re-
lease of cytochrome c and of AIF. CD4 T cells were purified from
PBMC of normal donors using negative selection and incubated for 2 h
with either medium () or HIV-1LAI () at a MOI of 0.01, washed, and
cultured for 6 days with PHA/IL-2 () or unstimulated (). Cytosolic
extracts of CD4 T cells were analyzed for cytochrome c and AIF by
Western blotting. As a control of loading, actin was used. The percent-
ages of dying cells (% of PS cells) determined by flow cytometry using
annexin-V-FITC are indicated. The experiment is representative of
three independent experiments.
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suggests that the cell death program induced by HIV replica-
tion is distinct from necrosis (cell swelling) (60). Cell shrinkage,
mediated by apoptotic inducers, is believed to be tightly linked
to enhanced K efflux (61–63). Thus, it would be interesting to
determine whether cell volume is directly related to an efflux of
K during HIV-mediated cell death and if HIV deregulates the
continuous activity of the Na/K ATPase pump.
Cell death mediated by HIV is associated with a loss of m,
even when caspase activation is blocked, suggesting a crucial
role for mitochondria in the regulation of this cell death. The
loss of mitochondrial membrane potential is associated with
the release of cytochrome c and AIF from the mitochondria.
Among critical effectors, AIF, a flavoprotein, has been reported
to directly cause chromatin condensation in isolated nuclei and
participates in caspase-independent programmed cell death.
Although, AIF protein was detected in the cytosolic fraction of
HIV-infected CD4 T cells along with cytochrome c, isolated
nuclei treated with these extracts did not display the major
features of AIF-induced nuclei morphology (64), even when the
nuclei were incubated in the presence of zVAD-fmk. During
preparation of this manuscript, Ferri et al. (28) reported that
syncitia arising from the fusion of cells expressing gp120 with
cells expressing the CD4 and CXCR4 molecules complex spon-
taneously undergo cell death, displaying evidence of caspase
activation, loss of m, and the release of cytochrome c and AIF
from mitochondria. Although AIF has been assumed to be a
potent activator of programmed cell death, recent work has
suggested that AIF release from the mitochondria and trans-
location to the nucleus can occur in the absence of chromatin
condensation and cell death (38, 65). Moreover, the study of
AIF knockout mice suggests the existence of a third cell death
pathway independent of caspases and AIF (66). Although dis-
pensable for cell death, our data suggest that caspases are the
main nuclear effectors involved in HIV-mediated DNA conden-
sation and fragmentation, in which AIF is either not involved
or not a major contributory factor. Whether AIF participates in
other effector pathways of cell death remains to be
investigated.
The mechanism responsible for mitochondrial membrane
permeabilization has been reported to involve proapoptotic
FIG. 9. HIV-mediated cell death is
not related to a down-regulation in
Bcl-2 expression but to an increase of
Bax to the mitochondrial-enriched
HM fraction. CD4 T cells were puri-
fied, incubated for 2 h with either medium
alone (Uninfected) or HIV-1LAI (HIV-in-
fected) at an MOI of 0.01, washed, and
cultured with PHA and IL-2 for 6 days. A,
Bcl-2 expression (thick line) was assessed
by flow cytometry as compared with iso-
type mAb (dashed line), gated either on
live (high forward scatter) or dying cells
(low forward scatter). B, two-color flow
cytometry was assessed to visualize Bcl-2
expression and p24 antigen in live (high
forward scatter) CD4 T cells. C, p24 ex-
pression (thick line) compared with iso-
type mAb (dashed line) and m in CD4
T cells either uninfected (HIV) or in-
fected with HIV in the absence (HIV) or
in the presence of DDI (5 M) (HIV 
DDI). D, 15 g of protein from mitochon-
dria enriched HM fraction of uninfected
(), and HIV-infected CD4 T cells ()
incubated in the absence () or presence
() of DDI (5 M) were analyzed for the
presence of Bax by Western blotting. As
control of loading, the presence of the
voltage-dependent anion channel was de-
termined. Bax was quantified by scan
density using NIH Image 1.62. The per-
centages of dying cells (% of PS cells),
determined by flow cytometry using an-
nexin-V-FITC, is indicated. The experi-
ment is representative of two independ-
ent experiments.
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members of the Bcl-2 family, the permeability transition pore
complex, theadeninenucleotide translocator,and/or thevoltage-
dependent anion channel (67). It has been proposed that the
HIV-1 protease can cleave Bcl-2, thereby abolishing its mito-
chondrial membrane potential-inhibitory function (68). How-
ever, we observed that Bcl-2 expression was equivalent in
CD4 T cells, whether uninfected or HIV-infected, and West-
ern blot analysis did not show the presence of fragmented Bcl-2
(data not shown), suggesting that the loss of Bcl-2 may be a
consequence of cell death and not directly involved in the loss of
m. Upon death stimuli, Bax is rapidly translocated to the
mitochondria and induces the loss of m, cytochrome c re-
lease, and activation of caspases (69–72). Here, we showed that
the amount of Bax was more important in the mitochondria-
enriched heavy membrane fraction of HIV-infected CD4 T
cells than in that of uninfected and DDI-treated HIV-infected
CD4 T cells. It has been recently reported that HIV-1 induces
an up-regulation of Bax via a p53 pathway (73). Thus, the
result of Genini et al. (73) and our data suggest that HIV-1 may
induce both Bax up-regulation and Bax targeting to the mito-
chondria. However, the nature of the signals that may lead to
Bax translocation during HIV-1 infection remains an open
question.
Studies by Xiang et al. (39) have shown that inducible Bax
expression triggers rapid death even in the presence of caspase
inhibitors, and nonapoptotic death proceeds through the gen-
eration of reactive oxygen species (ROS). In our model, HIV-
infected CD4 T cells die with a nonapoptotic phenotype when
treated with the broad spectrum caspase inhibitor (zVAD-fmk).
Preliminary data measuring intracellular oxidant levels using
the oxidation-sensitive dye dihydroethidium indicate that the
levels of ROS in HIV-infected CD4 T cells were higher than in
uninfected CD4 T cells and that ROS levels decreased in the
presence of DDI. Thus, independently of caspase activation, the
ability of Bax to induce disruption of mitochondrial membrane
permeability might be expected to result in the disruption of
electron transport following cytochrome c release, loss of ATP
and an increase in ROS may ultimately cause a nonapoptotic
cell death (74).
At this stage, however, we cannot exclude other death path-
ways that result in increased mitochondrial membrane perme-
ability. Indeed, it has been recently proposed that Vpr (a pro-
tein encoded by HIV) is directly targeted to the mitochondrial
permeability transition pore complex and permeabilizes mito-
chondrial membranes in a cell-free system (27). The Vpr pro-
tein has been reported to kill lymphocytes, monocytes, and
neurons (26, 75, 76) and to induce mitochondrial dysfunction in
the yeast Saccharomyces cerevisiae (77). However, it may also
act as a negative regulator of cell death in human cell lines and
thymocytes (78, 79), and CEM T cells infected with a triple
FIG. 9—continued
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mutant (nef, vpr, and vpu deleted) derived from HIV-1 also
undergo cell death (80), suggesting that Vpr is dispensable for
HIV-mediated CD4 T cell depletion. Thus, the role of HIV-1
proteins in inducing cell death through the loss of m remains
to be elucidated, and other viral products may be involved in
this process.
In conclusion, our data suggest that HIV-1 infection of cy-
cling primary CD4 T cells results in a cell death process
associated with a mitochondrial deregulation (loss in m).
Caspases that mediate chromatin condensation and fragmen-
tation are the main effectors of the apoptotic phenotype but are
dispensable for cell death. Our data indicate a crucial role of
the mitochondria in the regulation of cell death induced by HIV
and suggest that the targeting of Bax to the mitochondria may
be a major contributory factor.
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